AMP-activated protein kinase as a drug target in chronic kidney disease

Soumaya Allouch, Shankar Munusamy

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Background: Chronic kidney disease (CKD) is a condition increasingly affecting millions of individuals worldwide and is ranked as the ninth leading cause of death in the United States. AMP-activated protein kinase (AMPK) is an energy sensor that plays a pivotal role in cellular homoeostasis. Deficiency in AMPK activity and autophagic signaling, and sustained activation of mammalian target of rapamycin (mTOR) signaling and endoplasmic reticulum (ER) stress have been shown to promote epithelial-to-mesenchymal transition (EMT) and renal cell apoptosis and contribute to CKD. Emerging evidences demonstrate that AMPK acts as a modulator of the aforementioned pathways that underpin the pathophysiology of CKD. Furthermore, pharmacological activators of AMPK such as metformin have been shown to exert renoprotective effects in experimental studies and improve clinical outcomes in patients with CKD. Objective: The current review focuses on the nephroprotective effects of AMPK and its utility as a therapeutic target for the prevention and treatment of CKD.

Original languageEnglish
Pages (from-to)709-720
Number of pages12
JournalCurrent Drug Targets
Volume19
Issue number6
DOIs
Publication statusPublished - 1 Jan 2018

Fingerprint

AMP-Activated Protein Kinases
Chronic Renal Insufficiency
Pharmaceutical Preparations
Endoplasmic Reticulum Stress
Epithelial-Mesenchymal Transition
Metformin
Sirolimus
Modulators
Cause of Death
Homeostasis
Chemical activation
Pharmacology
Apoptosis
Kidney
Sensors
Therapeutics

Keywords

  • AMP-activated protein kinase
  • Apoptosis
  • Autophagy
  • Chronic kidney disease
  • Endoplasmic reticulum stress
  • Epithelial-mesenchymal transition
  • Mammalian target of rapamycin
  • Metformin

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

AMP-activated protein kinase as a drug target in chronic kidney disease. / Allouch, Soumaya; Munusamy, Shankar.

In: Current Drug Targets, Vol. 19, No. 6, 01.01.2018, p. 709-720.

Research output: Contribution to journalReview article

@article{c7f63dd8e53149cf9ded9c6e62099c32,
title = "AMP-activated protein kinase as a drug target in chronic kidney disease",
abstract = "Background: Chronic kidney disease (CKD) is a condition increasingly affecting millions of individuals worldwide and is ranked as the ninth leading cause of death in the United States. AMP-activated protein kinase (AMPK) is an energy sensor that plays a pivotal role in cellular homoeostasis. Deficiency in AMPK activity and autophagic signaling, and sustained activation of mammalian target of rapamycin (mTOR) signaling and endoplasmic reticulum (ER) stress have been shown to promote epithelial-to-mesenchymal transition (EMT) and renal cell apoptosis and contribute to CKD. Emerging evidences demonstrate that AMPK acts as a modulator of the aforementioned pathways that underpin the pathophysiology of CKD. Furthermore, pharmacological activators of AMPK such as metformin have been shown to exert renoprotective effects in experimental studies and improve clinical outcomes in patients with CKD. Objective: The current review focuses on the nephroprotective effects of AMPK and its utility as a therapeutic target for the prevention and treatment of CKD.",
keywords = "AMP-activated protein kinase, Apoptosis, Autophagy, Chronic kidney disease, Endoplasmic reticulum stress, Epithelial-mesenchymal transition, Mammalian target of rapamycin, Metformin",
author = "Soumaya Allouch and Shankar Munusamy",
year = "2018",
month = "1",
day = "1",
doi = "10.2174/1389450118666170601130947",
language = "English",
volume = "19",
pages = "709--720",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "6",

}

TY - JOUR

T1 - AMP-activated protein kinase as a drug target in chronic kidney disease

AU - Allouch, Soumaya

AU - Munusamy, Shankar

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Chronic kidney disease (CKD) is a condition increasingly affecting millions of individuals worldwide and is ranked as the ninth leading cause of death in the United States. AMP-activated protein kinase (AMPK) is an energy sensor that plays a pivotal role in cellular homoeostasis. Deficiency in AMPK activity and autophagic signaling, and sustained activation of mammalian target of rapamycin (mTOR) signaling and endoplasmic reticulum (ER) stress have been shown to promote epithelial-to-mesenchymal transition (EMT) and renal cell apoptosis and contribute to CKD. Emerging evidences demonstrate that AMPK acts as a modulator of the aforementioned pathways that underpin the pathophysiology of CKD. Furthermore, pharmacological activators of AMPK such as metformin have been shown to exert renoprotective effects in experimental studies and improve clinical outcomes in patients with CKD. Objective: The current review focuses on the nephroprotective effects of AMPK and its utility as a therapeutic target for the prevention and treatment of CKD.

AB - Background: Chronic kidney disease (CKD) is a condition increasingly affecting millions of individuals worldwide and is ranked as the ninth leading cause of death in the United States. AMP-activated protein kinase (AMPK) is an energy sensor that plays a pivotal role in cellular homoeostasis. Deficiency in AMPK activity and autophagic signaling, and sustained activation of mammalian target of rapamycin (mTOR) signaling and endoplasmic reticulum (ER) stress have been shown to promote epithelial-to-mesenchymal transition (EMT) and renal cell apoptosis and contribute to CKD. Emerging evidences demonstrate that AMPK acts as a modulator of the aforementioned pathways that underpin the pathophysiology of CKD. Furthermore, pharmacological activators of AMPK such as metformin have been shown to exert renoprotective effects in experimental studies and improve clinical outcomes in patients with CKD. Objective: The current review focuses on the nephroprotective effects of AMPK and its utility as a therapeutic target for the prevention and treatment of CKD.

KW - AMP-activated protein kinase

KW - Apoptosis

KW - Autophagy

KW - Chronic kidney disease

KW - Endoplasmic reticulum stress

KW - Epithelial-mesenchymal transition

KW - Mammalian target of rapamycin

KW - Metformin

UR - http://www.scopus.com/inward/record.url?scp=85047773248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047773248&partnerID=8YFLogxK

U2 - 10.2174/1389450118666170601130947

DO - 10.2174/1389450118666170601130947

M3 - Review article

AN - SCOPUS:85047773248

VL - 19

SP - 709

EP - 720

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 6

ER -